Compliance and Tolerance to Oral AntiBiotherapy in Osteoarticular Infections (OTABIO)
Compliance and Tolerance to Oral AntiBiotherapy in Osteoarticular Infections
Hospices Civils de Lyon
60 participants
Jun 13, 2024
OBSERVATIONAL
Conditions
Summary
Bone and joint infections (BJI) are most often bacterial infections that can occur after surgery or de novo. They are rarely fatal in the short term, but are associated with significant morbidity, impaired quality of life and significant costs. Treatment of BJI is based on antibiotic therapy, often combined with surgery. Antibiotic therapy, at high doses, lasts a minimum of 6 weeks. It can be responsible for severe adverse effects. These characteristics (prolonged duration, multiple daily doses, and adverse effects) are known to negatively affect treatment adherence in general.
Eligibility
Inclusion Criteria4
- ≥ 18 years
- Diagnosis of osteoarticular infection
- Treatment with at least one oral antibiotic for a minimum expected duration ≥ 6 weeks with an expected end of treatment date
- Patient who was informed and did not object to participate in the study
Exclusion Criteria5
- Treatment for BJI with oral antibiotic without end of treatment date
- treatment for BJI with parenteral antibiotic only
- patient who doesn't have a telephone number or who doesn't want to give it
- Adults subject to a legal protection measure
- Pregnant or breastfeeding women
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Adherence will be measured 6 weeks (S6) and 3 months (M3) after the surgery. Tolerance will be mesured at baseline, and at 6 weeks (S6) and 3 months (M3) after the surgery. The compliance data collected will be compared by two methods (electronic pill dispensers and questionnaire). Patients will respond to a questionnaire about the tolerance of intraveinous antibiotics (between surgery and baseline) and oral antibiotics at baseline, and during the consultation at S6 and M3. Responses to the compliance questionnaire will be collected during a telephone interview by a member of the Croix-Rousse pharmacy at S6 and M3. The pill organizer data from S6 and M3 will be transferred to the software by a nurse.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05202964